Logo

Qvin’s Q-Pad Kit Receives the US FDA’s Approval as a Step to Revolutionize Women’s Health with Menstrual Sample Testing

Share this
Qvin

Qvin’s Q-Pad Kit Receives the US FDA’s Approval as a Step to Revolutionize Women’s Health with Menstrual Sample Testing

Shots:

  • The US FDA has approved Qvin’s Q-Pad and A1c Test, an at-home collection of menstrual samples to detect and monitor diabetic and pre-diabetic women. The kit measures the average blood sugar levels over a 3mos. period, by testing the A1c biomarkers in patients with diabetes
  • The Q-Pad includes a removable strip that upon collection of the menstrual sample can be removed and sent to CLIA-Certified laboratories for clinical testing. The results are then received by the user through Qvin’s app
  • Qvin jointly with researchers from academic institutions incl. Stanford University School of Medicine, has published peer-reviewed research identifying potential biomarkers that can be tracked through Q-Pad Kit incl. HPV screening for the prevention of cervical cancer

Ref: PR Newswire | Image: Qvin

Related News:- Pfizer and Myovant's Myfembree Receive the US FDA's Approval for Heavy Menstrual Bleeding Associated with Uterine Fibroids

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions